$1.71 Billion is the total value of Cormorant Asset Management, LP's 49 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 53.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | Buy | BRIDGEBIO PHARMA INC | $122,950,916 | +71.5% | 4,662,530 | +11.8% | 7.17% | +78.5% |
| AMAM | Buy | AMBRX BIOPHARMA INCsponsored ads | $114,122,424 | -27.9% | 9,923,689 | +3.2% | 6.66% | -24.9% |
| Buy | ARCELLX INC | $77,142,000 | +22.0% | 2,150,000 | +7.5% | 4.50% | +27.0% | |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $76,080,000 | -36.2% | 2,000,000 | +52.7% | 4.44% | -33.6% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $57,403,500 | +38.0% | 3,850,000 | +1.3% | 3.35% | +43.6% |
| OLMA | Buy | OLEMA PHARMACEUTICALS INC | $55,633,835 | +99.9% | 4,504,764 | +46.2% | 3.24% | +108.1% |
| Buy | STRUCTURE THERAPEUTICS INCsponsored ads | $53,262,327 | +122.3% | 1,056,373 | +83.3% | 3.11% | +131.5% | |
| IMVT | Buy | IMMUNOVANT INC | $47,027,750 | +350.7% | 1,225,000 | +122.7% | 2.74% | +369.7% |
| TARS | Buy | TARSUS PHARMACEUTICALS INC | $46,582,669 | +81.4% | 2,621,422 | +84.4% | 2.72% | +88.8% |
| CABA | Buy | CABALETTA BIO INC | $43,824,833 | +52.8% | 2,879,424 | +29.6% | 2.56% | +59.1% |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $32,770,625 | – | 1,101,904 | +100.0% | 1.91% | – |
| PHVS | Buy | PHARVARIS N V | $28,413,670 | +92.8% | 1,361,460 | +39.8% | 1.66% | +100.6% |
| New | RAYZEBIO INC | $26,246,239 | – | 1,182,263 | +100.0% | 1.53% | – | |
| KRTX | Buy | KARUNA THERAPEUTICS INC | $23,672,600 | +36.5% | 140,000 | +75.0% | 1.38% | +42.1% |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $21,755,000 | – | 1,900,000 | +100.0% | 1.27% | – |
| New | MARINUS PHARMACEUTICALS INC | $21,131,250 | – | 2,625,000 | +100.0% | 1.23% | – | |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $19,486,250 | +97.0% | 850,000 | +41.7% | 1.14% | +105.2% |
| INSM | New | INSMED INC | $14,518,750 | – | 575,000 | +100.0% | 0.85% | – |
| New | NEUMORA THERAPEUTICS INC. | $1,302,256 | – | 92,293 | +100.0% | 0.08% | – | |
| New | HARPOON THERAPEUTICS INC | $217,862 | – | 54,060 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.